Contributor Disclosures for Pediatrics, Scarlet Fever

Role Name Disclosure Details Author  Pamela L Dyne, MD, Associate Professor, Program Director, Department of Medicine, Division of Emergency Medicine, University of California at Los Angeles School of Medicine Nothing to disclose Details Coauthor  Peter Bloomfield, MD, MPH, Resident Physician, UCLA Medical Center/Olive View-UCLA Medical Center Emergency Medicine Residency Program Nothing to disclose Details Medical Editor  Garry Wilkes, MBBS, FACEM, Director of Emergency Medicine, Bunbury Health Service, Western Australia Country Health Service; Adjunct Associate Professor, School of Exercise, Biomedical and Health Sciences, Faculty of Computing, Health and Science, Edith Cowan University; Medical Director, St John Ambulance Service Nothing to disclose Details Pharmacy Editor  Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc Pfizer Inc Avanir Pharma Details Managing Editor  Grace M Young, MD, Associate Professor, Department of Pediatrics, University of Maryland Medical Center Nothing to disclose Details CME Editor  John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School Nothing to disclose Details Chief Editor  Richard G Bachur, MD, Assistant Professor of Pediatrics, Harvard Medical School; Associate Chief and Fellowship Director, Attending Physician, Division of Emergency Medicine, Children's Hospital of Boston Nothing to disclose Details CONTRIBUTOR DISCLOSURE FORM Contributor Name: Pamela L Dyne  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: Peter Bloomfield, Coauthor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Garry Wilkes  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication CONTRIBUTOR DISCLOSURE FORM Contributor Name: Mary L Windle  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Pfizer Inc Stock Investment from broker recommendation   Avanir Pharma Stock Investment from broker recommendation   Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: Grace M Young, Managing Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: John Halamka  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication CONTRIBUTOR DISCLOSURE FORM Contributor Name: Richard G Bachur  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication